Allergy and Immunology, Allergy · Colorado Springs, CO
NPI
1679573588
Since 2005
Specialty
Allergy and Immunology, Allergy
Code 207KA0200X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
2709 N Tejon Street
Colorado Springs, CO, 80907
Phone (719) 473-0872
Groups this clinician bills Medicare through
Medicare paid, 2024
$127K
7,400 services
Medicare patients, 2024
160
Average age 71
Drug cost, 2024
$2.9M
626 prescriptions
Company payments, 2025
$116K
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel F Soteres was code 95004 (test - miscellaneous), 2,778 times for 42 patients. In total Daniel F Soteres billed 7,400 services in 22 codes, and Medicare paid $127K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2008-07-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95004 Test - Miscellaneous | Office | 2,778 | 42 | $2.79 | $7,739 |
| 95165 Treatment - Miscellaneous | Office | 667 | 31 | $11.39 | $7,598 |
| 95117 Treatment - Miscellaneous | Office | 520 | 29 | $8.98 | $4,667 |
| 95024 Test - Miscellaneous | Office | 333 | 27 | $6.51 | $2,167 |
| 99214 Office E&M - Established | Office | 136 | 95 | $91.99 | $13K |
| 94375 Pulmonary Function Testing | Office | 122 | 84 | $27.26 | $3,326 |
| 99213 Office E&M - Established | Office | 96 | 55 | $64.69 | $6,211 |
| 96401 Chemotherapy Administration | Office | 41 | 11 | $56.82 | $2,330 |
| 99204 Office E&M - New | Office | 39 | 39 | $132.35 | $5,162 |
| 94060 Pulmonary Function Testing | Office | 14 | 14 | $27.16 | $380 |
By year: 2022 $68K for 6,432 services; 2023 $49K for 5,244 services; 2024 $127K for 7,400 services.
Medicare prescription drug claims, 2024
In 2024, the drug Daniel F Soteres prescribed most often to Medicare patients was Montelukast Sodium, with 78 prescriptions and refills. In total Daniel F Soteres wrote 626 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 78 | 154 | 25 | $610 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 50 | 63 | 28 | $1,511 |
| Symbicort Budesonide/Formoterol Fumarate | 48 | 82 | 12 | $18K |
| Azelastine Hcl Generic | 42 | 65 | 20 | $1,279 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 40 | 58 | 12 | $36K |
| Fluticasone Propionate Generic | 40 | 81 | 18 | $730 |
| Takhzyro Lanadelumab-Flyo | 38 | 38 | Under 11 | $1.6M |
| Privigen Immun Glob G(Igg)/Pro/Iga 0-50 | 22 | 22 | Under 11 | $58K |
| Xolair Omalizumab | 21 | 21 | Under 11 | $41K |
| Spiriva Respimat Tiotropium Bromide | 17 | 40 | Under 11 | $18K |
| Ipratropium Bromide Generic | 16 | 18 | Under 11 | $541 |
| Wixela Inhub Fluticasone Propion/Salmeterol | 16 | 40 | Under 11 | $2,962 |
| Breo Ellipta Fluticasone/Vilanterol | 15 | 24 | Under 11 | $9,306 |
| Icatibant Icatibant Acetate | 14 | 14 | Under 11 | $182K |
| Advair Diskus Fluticasone Propion/Salmeterol | 13 | 25 | Under 11 | $4,558 |
Brand drugs: 335 claims; generic drugs: 291 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel F Soteres $116K ($116K in general payments such as food, travel and fees) from 23 companies. The largest payer was Takeda Pharmaceuticals U.S.A., Inc. with $33K.
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 45 | $33K |
| Pharming Healthcare, Inc. | 15 | $14K |
| BioCryst US Sales Co., LLC | 17 | $13K |
| Ionis Pharmaceuticals, Inc. IONS | 20 | $13K |
| AstraZeneca Pharmaceuticals LP AZN | 42 | $13K |
| CSL Behring CSL.AX | 17 | $11K |
| BioCryst Pharmaceuticals, Inc. BCRX | 4 | $11K |
| Genzyme Corporation SNY | 18 | $4,119 |
| Novartis Pharmaceuticals Corporation NVS | 22 | $1,436 |
| Genentech USA, Inc. ROG.SW | 10 | $243 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.